Scholarlink

<p>Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) represents less than 0.01% of all ovarian malignancies which affects mostly young women. Most cases are caused by a pathogenic variant (PV) in <i>SMARCA4</i> gene. Prognosis correlates directly with FIGO stage and multi-modal treatment including optimal cytoreductive surgery plus multi-agent platinum-based chemotherapy is recommended. A case of a 20-year-old female diagnosed with SCCOHT is presented. After surgery, she underwent six cycles of a platinum-based chemotherapy regimen consolidated with an autologous stem cell transplant. She was the first patient diagnosed with SCCOHT to receive a bone marrow transplant in Portugal and, 28&#xa0;months after the initial diagnosis, has no evidence of relapse. The authors discuss the management of this clinical case in parallel with an updated literature review, and the most recent International SCCOHT Consortium (ISC) guidelines, with emphasis on the role of autologous stem cell transplantation in the early stages of this disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early-stage small cell carcinoma of the ovary hypercalcemic type: autologous stem cell transplantation as standard primary treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月28日

查看全文
  • Teresa Lopes Bruno,
  • Catarina Cardoso,
  • Joana Ferreira,
  • Fátima Vaz

摘要

Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) represents less than 0.01% of all ovarian malignancies which affects mostly young women. Most cases are caused by a pathogenic variant (PV) in SMARCA4 gene. Prognosis correlates directly with FIGO stage and multi-modal treatment including optimal cytoreductive surgery plus multi-agent platinum-based chemotherapy is recommended. A case of a 20-year-old female diagnosed with SCCOHT is presented. After surgery, she underwent six cycles of a platinum-based chemotherapy regimen consolidated with an autologous stem cell transplant. She was the first patient diagnosed with SCCOHT to receive a bone marrow transplant in Portugal and, 28 months after the initial diagnosis, has no evidence of relapse. The authors discuss the management of this clinical case in parallel with an updated literature review, and the most recent International SCCOHT Consortium (ISC) guidelines, with emphasis on the role of autologous stem cell transplantation in the early stages of this disease.